邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读

袁群生,  李雪梅

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(3): 213-218
袁群生, 李雪梅. 2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读[J]. 协和医学杂志, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
引用本文: 袁群生, 李雪梅. 2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读[J]. 协和医学杂志, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
shu
Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
Citation: Qun-sheng YUAN, Xue-mei LI. Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 213-218. doi: 10.3969/j.issn.1674-9081.2018.03.005
shu

2017年KDIGO关于慢性肾脏病矿物质及骨异常临床实践指南更新与解读

doi: 10.3969/j.issn.1674-9081.2018.03.005

  • 中国医学科学院 北京协和医学院 北京协和医院肾内科, 北京 100730

详细信息
    通讯作者:

    李雪梅 电话:010-69154056, E-mail:lixmpumch@126.com

  • 中图分类号: R58

Updates and Interpretation on 2017 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder

  • Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 2009年改善全球肾脏病预后组织(kidney disease:improving global outcomes, KDIGO)发布了关于慢性肾脏病矿物质及骨异常(chronic kidney disease-mineral and bone disorder, CKD-MBD)的诊断、评估、预防和治疗的临床实践指南, 为广大临床工作者对CKD-MBD的认识及诊疗提供了详细的指导意见。但指南缺少针对临床终点事件的随机对照研究(randomized control trial, RCT)证据, 故其证据质量不高。随着此后多项RCT研究和前瞻性队列研究结果的公布, KDIGO工作组经过对相关新证据的评估和充分讨论, 于2017年6月对该指南进行了选择性更新, 主要涉及CKD-MBD中骨病的诊断及钙、磷和甲状旁腺素的管理等。本文就主要的更新内容进行解读, 揭示其临床意义。
    Abstract: The Kidney Disease:Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) was originally published in 2009, which assists practitioners in clinical diagnosis, prevention, and treatment of CKD-MBD. However, the Guideline Work Group acknowledged the lack of sufficient evidence for the base of recommendations. The Guideline included specific research recommendations to encourage investigators to help fill the gaps and bolster the evidence base. With the accumulation of related results of multiple randomized and controlled trials and prospective cohort studies since 2009, 2017 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update on the prior guideline published in 2009. Specifically, the topic areas for which updated recommendations are issued include the diagnosis of bone abnormalities in CKD-MBD, treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of parathyroid hormone abnormalities in CKD-MBD, and so on. A total of 12 recommendations were reevaluated and updated based on new data. This report interprets the updates on 2017 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD and describes the results of these proceedings, which highlights the significance of KDIGO CKD-MBD guideline in clinical practice.
    • HTML全文
    • 参考文献(34)
  • [1] Kidney disease:improving global outcomes (KDIGO) CKD-MBD work group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2009, 76:S1-S130. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM19644521
    [2] Kidney disease:improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017, 7:1-59. doi:  10.1016/j.kisu.2017.04.001
    [3] Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease[J]. Kidney Int, 2000, 58:396-399. doi:  10.1046/j.1523-1755.2000.00178.x
    [4] Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States[J]. J Am Soc Nephrol, 2006, 17:3223-3232. doi:  10.1681/ASN.2005111194
    [5] Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population[J]. Am J Kidney Dis, 2004, 44:672-679. doi:  10.1016/S0272-6386(04)00958-8
    [6] Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients[J]. Kidney Int, 2014, 85:166-173. doi:  10.1038/ki.2013.279
    [7] Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness of bonemineral density and biochemical markers of bone turnover inpredicting fracture in CKD stage 5D patients-a single-centercohort study[J]. Nephrol Dial Transplant, 2012, 27:345-351. doi:  10.1093/ndt/gfr317
    [8] West SL, Lok CE, Langsetmo L, et al. Bone mineral density predictsfractures in chronic kidney disease[J]. J Bone Miner Res, 2015, 30:913-919. doi:  10.1002/jbmr.2406
    [9] Haghverdi F, Mortaji S, Soltani P, et al. Effect of raloxifene onparathyroid hormone in osteopenic and osteoporoticpostmenopausal women with chronic kidney disease stage 5[J]. Iran J Kidney Dis, 2014, 8:461-466. http://europepmc.org/abstract/med/25362221
    [10] Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects ofdenosumab on fracture and bone mineral density by level of kidneyfunction[J]. J Bone Miner Res, 2011, 26:1829-1835. doi:  10.1002/jbmr.403
    [11] EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J]. N Engl J Med, 2012, 367:2482-2494. doi:  10.1056/NEJMoa1205624
    [12] Block GA, Kilpatrick RD, Lowe KA, et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization inpatients on hemodialysis[J]. Clin J Am Soc Nephrol, 2013, 8:2132-2140. doi:  10.2215/CJN.04260413
    [13] Chartsrisak K, Vipattawat K, Assanatham M, et al. Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients[J]. BMC Nephrol, 2013, 14:14-20. doi:  10.1186/1471-2369-14-14
    [14] Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality inpatients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2010, 5:2251-2257. doi:  10.2215/CJN.00810110
    [15] Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and bone disease in haemodialysis patients:which optimal targets?[J]. Nephrol Dial Transplant, 2013, 28:360-367. doi:  10.1093/ndt/gfs404
    [16] Gross P, Six I, Kamel S, et al. Vascular toxicity of phosphate in chronic kidney disease:beyond vascular calcification[J]. Circ J, 2014, 78:2339-2346. doi:  10.1253/circj.CJ-14-0735
    [17] Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J]. Kidney Int, 2013, 83:959-966. doi:  10.1038/ki.2012.403
    [18] Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD[J]. J Am Soc Nephrol, 2012, 23:1407-1415. doi:  10.1681/ASN.2012030223
    [19] Di Iorio B, Bellasi A, Russo D, et al. Mortality in kidney disease patients treated with phosphate binders:a randomized study[J]. Clin J Am Soc Nephrol, 2012, 7:487-493. doi:  10.2215/CJN.03820411
    [20] Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients:results of an openlabel 24-month randomized clinical trial[J]. Am J Kidney Dis, 2013, 62:771-778. doi:  10.1053/j.ajkd.2013.03.023
    [21] Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality inpatients with chronic kidney disease:an updated systematic reviewand meta-analysis[J]. Lancet, 2013, 382:1268-1277. doi:  10.1016/S0140-6736(13)60897-1
    [22] Karavetian M, de Vries N, Elzein H, et al. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon[J]. Patient Educ Couns, 2015, 98:1116-1122. doi:  10.1016/j.pec.2015.05.005
    [23] Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population[J]. Nephrol Dial Transplant, 2011, 26:1948-1955. doi:  10.1093/ndt/gfq219
    [24] Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets[J]. Kidney Int, 2012, 81:1116-1122. doi:  10.1038/ki.2011.490
    [25] St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006[J]. Clin J Am Soc Nephrol, 2009, 4:354-360. doi:  10.2215/CJN.05241008
    [26] Denburg MR, Tsampalieros AK, de Boer IH, et al. Mineral metabolism and cortical volumetric bone mineral density inchildhood chronic kidney disease[J]. J Clin Endocrinol Metab, 2013, 98:1930-1938. doi:  10.1210/jc.2012-4188
    [27] Ok E, Asci G, Bayraktaroglu S, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis[J]. J Am Soc Nephrol, 2016, 27:2475-2486. doi:  10.1681/ASN.2015030268
    [28] Spasovski G, Gelev S, Masin-Spasovska J, et al. Improve-ment of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium[J]. Bone, 2007, 41:698-703. doi:  10.1016/j.bone.2007.06.014
    [29] Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial[J]. JAMA, 2012, 307:674-684. doi:  10.1001/jama.2012.120
    [30] Li XH, Feng L, Yang ZH, et al. The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases:a systematic review and meta-analysis[J]. Nephrology (Carlton), 2015, 20:706-714. doi:  10.1111/nep.12505
    [31] Parfey PS, Drüeke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis:the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial[J]. Clin J Am Soc Nephrol, 2015, 10:791-799. doi:  10.2215/CJN.07730814
    [32] Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet:the EVOLVE trial[J]. J Clin Endocrinol Metab, 2013, 98:4834-4844. doi:  10.1210/jc.2013-2975
    [33] Behets GJ, Spasovski G, Sterling LR, et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Int, 2015, 87:846-856. doi:  10.1038/ki.2014.349
    [34] Raggi P, Chertow GM, Torres PU, et al. The advance study:a randomized study to evaluate the effects of cinacalcet plus low-dosevitamin D on vascular calcification in patients on hemodialysis[J].Nephrol Dial Transplant, 2011, 26:1327-1339. doi:  10.1093/ndt/gfq725
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  366
  • HTML全文浏览量:  48
  • PDF下载量:  975
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-08
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！